Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Yelena Bisharyan
Advertisement
Yelena Bisharyan is research scientist I at the department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY
Articles by Yelena Bisharyan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
3
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
4
After the Pivot: What In Vivo Cell Therapy Offers, and What It Still Has to Prove
5